🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Singapore / NCT07779941
Starting soon Not applicable

A Pilot Evaluation of Refractive Error Progression in Pre-Myopic Children in Singapore With and Without Myopia Control Spectacles

NCT07779941 · tracked via the Priya Life Science Singapore tracker
Phase
Not applicable
Started
2026-08
Last updated
2026-08-21

Condition(s) studied

MyopiaPre-myopia

Investigational drug(s) / intervention(s)

Zeiss MyoActive lensesSingle Vision Lenses

Zeiss MyoActive lenses: The novel ZEISS MyoActive lens was designed to introduce simultaneous myopic defocus at the retina. Early studies, including interim results from the ongoing trial NCT06563700, have shown promise in reducing myopia progression in already-myope children. However, its utility in pre-myopic children remains underexplored, and no current optical strategy has been validated for delaying the transition from pre-myopia to clinical myopia.

Single Vision Lenses: Patients will be fitted with a pair of plano single vision glasses.

Study summary

This study aims to find out whether ZEISS MyoActive lenses can help prevent short-sightedness from developing in children. We aim to recruit at least 50 children in total for this study.

Myopia (short-sightedness) is becoming increasingly common in children worldwide. Early onset of myopia often leads to faster progression and a higher chance of developing high myopia, which increases the risk of serious eye conditions that can affect vision in adulthood, such as retinal detachment, glaucoma, and cataracts. Current treatments can slow the worsening of short-sightedness once children become myopic, but there is limited evidence on whether early intervention can delay myopia from developing in the first place.

This study will compare two types of commonly used spectacle lenses:

ZEISS MyoActive lenses, which are designed to provide a type of optical signal that may reduce the worsening of short-sightedness; and Standard single-vision lenses, which are the usual lenses prescribed for clear vision.

Children who join the study will be randomly assigned to wear one of these two lens types for 12 months. They will attend regular check-ups during this time so we can monitor their eye health and vision.

By randomly assigning children to one of these two lens types and following them over 12 months, we aim to determine whether ZEISS MyoActive lenses:

reduce the likelihood of developing short-sightedness, slow changes in how short-sighted a child's eyes are becoming and eye growth, and are safe, comfortable, and well-tolerated for everyday use. The findings from this study may help improve early myopia prevention strategies and potentially reduce future risks of high myopia and its associated eye conditions.

Eligibility

Sex
ALL
Min age
6 Years
Max age
12 Years
Healthy volunteers
Accepted
Inclusion Criteria Participants enrolled in the trial must: 1. be accompanied by a parent or guardian who is able to read and comprehend English and sign a record of informed consent/assent; 2. be able to understand and participate in the Assent process; 3. at baseline, be within the age range of 6 to 12 years old inclusive; 4. No prior spectacle correction 5. Cycloplegic spherical equivalent (SE) 0.00 to + 2.00 D 6. Astigmatism of less than -1.50D 7. Anisometropia of not more than 1.50D 8. At least 1 parent or more with myopia Exclusion Criteria Participants enrolled in the trial must NOT have: * Any pre-existing systemic or ocular condition, including infection or disease that is likely to affect visual acuity and refractive error; * Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. * Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology in an adverse or beneficial manner at enrolment and/or during the study. NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the study product is used. * History of eye trauma * Amblyopia * Strabismus * History of any form of optical correction * Any concomitant myopia control treatment including atropine eyedrops, contact lenses or other myopia control glasses. The Investigator may, at their discretion, exclude anyone who they believe may not be able to fulfil the study requirements or it is believed to be in the participant's best interests.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Singapore National Eye Centre Singapore Singapore

More Singapore National Eye Centre trials in Singapore

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07779941 on ClinicalTrials.gov ↗ ← All trials in Singapore